pharma · Infertility in women undergoing assisted reproductive technologies (ART) · Intermediate risk, non-muscle invasive bladder cancer
Ferring Pharmaceuticals
Ferring Pharmaceuticals clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- -, St-Prex, 1162, CH, Mumbai
- Founded
- 1950
- Employees
- 6,228
- Programs
- 13
- Drugs
- 23
- Patents
- 0
Ferring Pharmaceuticals projects
3 ClinicalTrials.gov programs sponsored by Ferring Pharmaceuticals.
Ferring Pharmaceuticals has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ADSTILADRIN
Ferring Pharmaceuticals
Low-grade upper track urothelial carcinoma (LG-UTUC)
1 trial -
REKOVELLE for Idiopathic male infertility (in…
Ferring Pharmaceuticals
Idiopathic male infertility (including oligoasthenozoospermia).
1 trial -
TRI-001-01
Ferring Pharmaceuticals
Patients with Chronic Limb Threatening Ischemia (CLTI) due to Peripheral Arterial Disease (PAD)
1 trial
Frequently asked questions
How many clinical projects does Ferring Pharmaceuticals have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.